Advertisement
MDT or SNN or STE
Which Stock Would AI Choose? Medtronic (MDT) vs. Smith & Nephew (SNN) vs. STERIS (STE) Stock Comparison
Key Takeaways
- MDT (Medtronic plc) offers the largest scale and a 3%-plus dividend yield, but shares remain pressured by spinoff costs and robotics investment.
- SNN (Smith & Nephew plc) is the smallest of the three and recently cut its revenue outlook amid weak U.S. knee implant demand.
- STE (STERIS plc) delivers the most consistent recurring-revenue profile, but a sizable new manufacturing investment has added near-term cost pressure.
- All three names are medical-technology companies, yet their growth drivers, valuation sensitivity, and recent momentum diverge meaningfully.
- Relative performance and market positioning suggest a contrast between turnaround stories and steady compounding businesses.
Introduction
Medtronic, Smith & Nephew, and STERIS are three widely followed medical-device and healthcare-technology companies, but they occupy very different corners of the sector. A stock comparison across these names is useful for investors weighing large-cap stability against turnaround potential and recurring-revenue quality. Each stock has faced distinct pressures in recent market activity, from portfolio reshaping to reimbursement changes and capital-investment cycles. Understanding how their business models, momentum, and risk profiles compare can help traders and investors assess relative performance and market positioning within the broader medical technology space. The sections below examine each company on a balanced, factual basis.
MDT Overview and Recent Performance
MDT, Medtronic plc, is an Ireland-domiciled medical technology leader spanning cardiovascular, neuroscience, medical-surgical, and diabetes portfolios. In recent quarters it has reported stronger enterprise revenue growth, led by its cardiovascular franchise and an 80%-plus surge in cardiac ablation solutions tied to pulsed field ablation adoption. Management also raised its full-year organic revenue and earnings per share (EPS) guidance. At the same time, shares have underperformed over a multi-year horizon, and the company continues to absorb costs related to the spinoff of its diabetes business and heavy investment in its Hugo robotic-assisted surgery platform. A dividend yielding roughly 3% and 49 consecutive years of payout increases support income-focused investors, while a forward price-to-earnings (P/E) ratio below the industry average reflects persistent skepticism about the pace of the turnaround.
SNN Overview and Recent Performance
SNN, Smith & Nephew plc, is a British medical products company operating across Orthopaedics, Sports Medicine and Ear, Nose, and Throat (ENT), and Advanced Wound Management. Recent market activity has been dominated by a downward revision to its full-year revenue outlook, cut to roughly 4% from about 6%, after weaker-than-expected quarterly results. U.S. knee implant revenue declined materially, which management attributed primarily to company-specific portfolio gaps rather than broad market weakness, while Advanced Wound Bioactives faced reimbursement pressure for skin substitutes. Offsetting this, Sports Medicine and ENT delivered solid growth, and the company maintained its trading profit, free cash flow, and return-on-invested-capital targets, supported by efficiency savings and tariff refunds. Sentiment remains cautious as investors look for tangible evidence that its turnaround strategy is translating into sustained improvement.
STE Overview and Recent Performance
STE, STERIS plc, provides infection prevention products and services across Healthcare, Applied Sterilization Technologies (AST), and Life Sciences segments. Its business is anchored by a large recurring base of consumables and services, which now represent a substantial majority of revenue. Recent results showed solid adjusted EPS growth and mid-to-high-single-digit revenue gains, though a modest top-line miss and a large new investment drew investor attention. STERIS announced a $600 million formulated chemistries Center of Excellence, its largest single-site commitment to date, accompanied by higher capital spending, a reduced free cash flow outlook, and restructuring charges. While this supports long-term capacity and efficiency, it introduces execution risk in the near term. Valuation remains elevated relative to its medtech peers, reflecting confidence in the durability of its recurring-revenue model.
Trending AI Robots
Tickeron operates hundreds of AI Trading Bots that collectively monitor and trade thousands of different tickers across markets. Because these bots vary widely in trading style, strategy, timeframe, historical performance, and the specific set of tickers they follow, only the strongest and most suitable for current market conditions are featured in the curated Trending AI Robots section. This rotating selection highlights bots demonstrating favorable consistency and adaptability, helping users identify automated strategies aligned with today's environment. If you are exploring a systematic approach to names like MDT, SNN, and STE, reviewing the current trending lineup may offer a useful starting point.
Head-to-Head Comparison
These three companies differ most sharply in business model and growth drivers. Medtronic is a diversified, large-cap device maker pursuing growth through targeted acquisitions and robotics, with a value-oriented valuation and income support. Smith & Nephew is a focused orthopaedics and wound-care turnaround, more sensitive to procedure volumes and reimbursement policy, and currently trading at a lower multiple amid execution concerns. STERIS leans on sticky, recurring consumables and sterilization services, which produces steadier growth but a higher valuation.
On recent momentum, STERIS has shown the most stable fundamentals, though its shares pulled back on spending concerns. Medtronic's improving revenue growth has not yet translated into sustained share-price appreciation. Smith & Nephew carries the clearest near-term negative revision. Risk factors also diverge: Medtronic faces spinoff and robotics ramp costs; Smith & Nephew faces U.S. knee and reimbursement headwinds; and STERIS faces tariff, inflation, and capital-project execution risk. Sector exposure is broadly similar, but market sentiment currently favors recurring-revenue stability over cyclical turnarounds.
Tickeron AI Verdict
Based on observable factors such as trend consistency, revenue durability, and relative positioning, Tickeron's AI would likely favor STE among these three. Its recurring-revenue base, steady segment growth, and clear long-term catalysts provide a more stable trend profile than the turnaround dynamics currently weighing on SNN and the persistent valuation skepticism surrounding MDT. That said, the elevated capital-spending burden and higher valuation introduce uncertainty, and the outcome would depend on how execution and momentum evolve. This reflects a probabilistic assessment rather than a definitive prediction.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
MDT sees its 50-day moving average cross bullishly above its 200-day moving average
The 50-day moving average for MDT moved above the 200-day moving average on September 17, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 12, 2026. You may want to consider a long position or call options on MDT as a result. In 48 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 56%.
The Moving Average Convergence Divergence (MACD) for MDT just turned positive on October 12, 2026. Looking at past instances where MDT's MACD turned positive, the stock continued to rise in 27 of 43 cases over the following month. The odds of a continued upward trend are 63%.
MDT moved above its 50-day moving average on October 12, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for MDT crossed bullishly above the 50-day moving average on October 16, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 53%.
Following a +2.62% 3-day Advance, the price is estimated to grow further. Considering data from situations where MDT advanced for three days, in 170 of 316 cases, the price rose further within the following month. The odds of a continued upward trend are 54%.
Bearish Trend Analysis
The 10-day RSI Indicator for MDT moved out of overbought territory on October 16, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In 12 of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at 46%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 9 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MDT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
MDT broke above its upper Bollinger Band on October 12, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for MDT entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 27 (best 1 - 100 worst), indicating outstanding price growth. MDT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 57 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 59 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.430) is normal, around the industry mean (2.914). P/E Ratio (23.328) is within average values for comparable stocks, (1.904). Projected Growth (PEG Ratio) (1.608) is also within normal values, averaging (11.052). Dividend Yield (0.030) settles around the average of (0.009) among similar stocks. P/S Ratio (3.176) is also within normal values, averaging (40.124).
The Tickeron SMR rating for this company is 68 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MDT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
SNN's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for SNN turned positive on October 05, 2026. Looking at past instances where SNN's MACD turned positive, the stock continued to rise in 37 of 50 cases over the following month. The odds of a continued upward trend are 74%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 07, 2026. You may want to consider a long position or call options on SNN as a result. In 46 of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 55%.
SNN moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for SNN crossed bullishly above the 50-day moving average on October 20, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 62%.
Following a +4.42% 3-day Advance, the price is estimated to grow further. Considering data from situations where SNN advanced for three days, in 192 of 333 cases, the price rose further within the following month. The odds of a continued upward trend are 58%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 11 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SNN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 57%.
SNN broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for SNN entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 16 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.491) is normal, around the industry mean (2.914). P/E Ratio (20.775) is within average values for comparable stocks, (1.904). Projected Growth (PEG Ratio) (1.035) is also within normal values, averaging (11.052). Dividend Yield (0.039) settles around the average of (0.009) among similar stocks. P/S Ratio (1.905) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 47 (best 1 - 100 worst), indicating steady price growth. SNN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 82 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SNN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
STE in upward trend: price rose above 50-day moving average on October 15, 2026
STE moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend. In 26 of 44 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 59%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 08, 2026. You may want to consider a long position or call options on STE as a result. In 50 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 52%.
The Moving Average Convergence Divergence (MACD) for STE just turned positive on September 29, 2026. Looking at past instances where STE's MACD turned positive, the stock continued to rise in 24 of 46 cases over the following month. The odds of a continued upward trend are 52%.
The 10-day moving average for STE crossed bullishly above the 50-day moving average on October 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 7 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 41%.
Following a +3.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where STE advanced for three days, in 152 of 315 cases, the price rose further within the following month. The odds of a continued upward trend are 48%.
The Aroon Indicator entered an Uptrend today. In 98 of 200 cases where STE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 49%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 9 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where STE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 57%.
STE broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. STE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 66 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 71 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 77 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.141) is normal, around the industry mean (2.914). P/E Ratio (28.242) is within average values for comparable stocks, (1.904). Projected Growth (PEG Ratio) (1.760) is also within normal values, averaging (11.052). Dividend Yield (0.012) settles around the average of (0.009) among similar stocks. P/S Ratio (3.423) is also within normal values, averaging (40.124).
The Tickeron Profit vs. Risk Rating rating for this company is 78 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. STE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.
MDT | SNN | STE | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 37 | 39 | 13 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 59 Fair valued | 16 Undervalued | 77 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | 78 | |
SMR RATING 1..100 | 68 | 92 | 66 | |
PRICE GROWTH RATING 1..100 | 27 | 47 | 44 | |
P/E GROWTH RATING 1..100 | 57 | 82 | 71 | |
SEASONALITY SCORE 1..100 | 50 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SNN's Valuation (16) in the Medical Specialties industry is somewhat better than the same rating for MDT (59) and is somewhat better than the same rating for STE (77). This means that SNN's stock grew somewhat faster than MDT’s and somewhat faster than STE’s over the last 12 months.
STE's Profit vs Risk Rating (78) in the Medical Specialties industry is in the same range as SNN (100) and is in the same range as MDT (100). This means that STE's stock grew similarly to SNN’s and similarly to MDT’s over the last 12 months.
STE's SMR Rating (66) in the Medical Specialties industry is in the same range as MDT (68) and is in the same range as SNN (92). This means that STE's stock grew similarly to MDT’s and similarly to SNN’s over the last 12 months.
MDT's Price Growth Rating (27) in the Medical Specialties industry is in the same range as STE (44) and is in the same range as SNN (47). This means that MDT's stock grew similarly to STE’s and similarly to SNN’s over the last 12 months.
MDT's P/E Growth Rating (57) in the Medical Specialties industry is in the same range as STE (71) and is in the same range as SNN (82). This means that MDT's stock grew similarly to STE’s and similarly to SNN’s over the last 12 months.
| MDT | SNN | STE | |
|---|---|---|---|
| RSI ODDS (%) | 1 day ago 46% | 1 day ago 47% | 1 day ago 59% |
| Stochastic ODDS (%) | 1 day ago 48% | 1 day ago 54% | 1 day ago 62% |
| Momentum ODDS (%) | 1 day ago 56% | 1 day ago 55% | 1 day ago 52% |
| MACD ODDS (%) | 1 day ago 63% | 1 day ago 74% | 1 day ago 52% |
| TrendWeek ODDS (%) | 1 day ago 56% | 1 day ago 56% | 1 day ago 52% |
| TrendMonth ODDS (%) | 1 day ago 50% | 1 day ago 58% | 1 day ago 47% |
| Advances ODDS (%) | 9 days ago 54% | 9 days ago 58% | 12 days ago 48% |
| Declines ODDS (%) | 5 days ago 56% | 5 days ago 57% | 5 days ago 57% |
| BollingerBands ODDS (%) | 1 day ago 53% | 1 day ago 59% | 1 day ago 70% |
| Aroon ODDS (%) | 1 day ago 46% | 1 day ago 59% | 1 day ago 49% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MDT’s FA Score shows that 1 FA rating(s) are green while SNN’s FA Score has 1 green FA rating(s), and STE’s FA Score reflects 0 green FA rating(s).
- MDT’s FA Score: 1 green, 4 red.
- SNN’s FA Score: 1 green, 4 red.
- STE’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MDT’s TA Score shows that 6 TA indicator(s) are bullish while SNN’s TA Score has 5 bullish TA indicator(s), and STE’s TA Score reflects 6 bullish TA indicator(s).
- MDT’s TA Score: 6 bullish, 5 bearish.
- SNN’s TA Score: 5 bullish, 5 bearish.
- STE’s TA Score: 6 bullish, 4 bearish.
Price Growth
MDT (@Medical/Nursing Services) experienced а +0.70% price change this week, while SNN (@Medical/Nursing Services) price change was +6.15% , and STE (@Medical/Nursing Services) price fluctuated +4.26% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -0.51%. For the same industry, the average monthly price growth was -9.72%, and the average quarterly price growth was -10.64%.
Reported Earning Dates
MDT is expected to report earnings on Nov 17, 2026.
SNN is expected to report earnings on Nov 04, 2026.
STE is expected to report earnings on Nov 04, 2026.
Industries' Descriptions
@Medical/Nursing Services (-0.51% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
Advertisement
MDT and
Correlation & Price change
A.I.dvisor indicates that over the last year, MDT has been loosely correlated with SYK. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if MDT jumps, then SYK could also see price increases.
SNN and
Correlation & Price change
A.I.dvisor indicates that over the last year, SNN has been loosely correlated with MDT. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if SNN jumps, then MDT could also see price increases.
| Ticker / NAME | Correlation To SNN | 1D Price Change % | ||
|---|---|---|---|---|
| SNN | 100% | -0.16% | ||
| MDT - SNN | 53% Loosely correlated | -1.22% | ||
| SYK - SNN | 50% Loosely correlated | +0.02% | ||
| OFIX - SNN | 47% Loosely correlated | -1.80% | ||
| ZBH - SNN | 46% Loosely correlated | -0.25% | ||
| GEHC - SNN | 46% Loosely correlated | +0.10% | ||
More | ||||
STE and
Correlation & Price change
A.I.dvisor indicates that over the last year, STE has been loosely correlated with SYK. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if STE jumps, then SYK could also see price increases.